Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06565026 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CS-206 in Patients With Sickle Cell Disease

StatusRecruiting
PhaseEarly Phase 1
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Re-verified, no change to tracked fieldsv3
  2. Start date changed from estimate of Aug 30, 2024 to Sep 2, 2024
    • Interventions: CS-101 (Genetic) to CS-206 (Genetic)
    • Secondary endpoints: details revised at 2 of 6 entries
    • Study title revised
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this open label, single-arm clinical study is to learn about the safety and efficacy of CS-101 injection in treating sickle cell disease.
Trial Details
NCT Number NCT06565026
Lead Sponsor CorrectSequence Therapeutics Co., Ltd
Collaborators: First Affiliated Hospital of Guangxi Medical University
Conditions
(from sponsor)		 Sickle Cell Disease
Related terms Anemia, Sickle Cell
Enrollment 5 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov